Latest Articles

Publication Date
Laparoscopic Assisted Neo-Cervico-Vaginal Anastomosis by Rail-Road Procedure In Cervico-Vaginal Atresia.

Cervico-vaginal atresia is a rare entity, difficult to diagnose and treat, with a higher rate of complications. It is classified as type 1b mullerian anomaly per ASRM and subclass C4 …

Published: July 17, 2026, midnight
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm

Published: July 16, 2026, 10:27 a.m.
Rheumatic Heart Disease: Inflammation, Immune Pathways, Valve Remodeling, and the Promise of SGLT2 Inhibitors.

Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …

Published: July 16, 2026, midnight
Leven Rambin reveals life-threatening surgery complication after endometriosis procedure - MSN

Leven Rambin reveals life-threatening surgery complication after endometriosis procedure MSN

Published: July 15, 2026, 9:13 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
TV star says doctors ‘nicked’ vital artery during routine procedure: ‘Lucky to be alive’ - Cleveland.com

TV star says doctors ‘nicked’ vital artery during routine procedure: ‘Lucky to be alive’ Cleveland.com

Published: July 15, 2026, 3:58 p.m.
TV star says doctors ‘nicked’ vital artery during routine procedure: ‘Lucky to be alive’ - OregonLive.com

TV star says doctors ‘nicked’ vital artery during routine procedure: ‘Lucky to be alive’ OregonLive.com

Published: July 15, 2026, 3:58 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Role of sRAGE in clinical heterogeneity and inflammation in endometriosis patients undergoing IVF; case-control study.

Endometriosis is a multifactorial, chronic inflammatory disorder that affects a substantial proportion of women during their reproductive years and is frequently associated with pelvic pain and infertility. Accumulating evidence suggests …

Published: July 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!